Frontlight ResearchEarly access
Active, not recruitingNo phase
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
Key facts
- Who runs it
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Where
- Baltimore and Washington D.C., United StatesSee the 2 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 40 people enrolled
- Started
- 19 Jul 2017
- Expected to end
- Dec 2030
- Type of study
- Interventional
- Treatments tested
- whole brain radiation therapy
- Record updated
- 30 June 2026
Who can take part
- Age
- 18 years to 100 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Histologic proof or unequivocal cytologic proof solid tumor malignancy. This may be obtained from either the primary or any metastatic site
- Mini Mental State Examination (MMSE) ≥24
- Age≥ 18 years
- Karnofsky Performance Status (KPS) ≥70
- Patient does not have metastases to the genu
- Patient must be scheduled to undergo treatment with whole brain radiation therapy (WBRT) to manage the brain metastases
- Patients of childbearing potential (male or female) must practice adequate contraception due to possible harmful effects of radiation therapy on an unborn child
- Patient must have the ability to understand and the willingness to sign a written informed consent document
- All patients must be informed of the investigational nature of this study and must be given written informed consent in accordance with institutional and federal guidelines
- Patient must have a minimal life expectancy of at least 6 months
- Patients receiving prior stereostatic radiosurgery (SRS) for brain metastases are eligible
Who cannot take part
- Prior WBRT
- Patients must not have a serious medical or psychiatric illness that would, in the opinion of the treating physician prevent informed consent or completion of protocol treatment, and/or follow-up visits
- MMSE<24
- Patient has brain metastases in the genu
- KPS<70
- Non-native English speakers will be excluded since patients often lose their faculty with the language they acquired second before their native language is affected in the context of cognitive decline. This could adversely affect performance on verbal cognitive tasks
- Patients with absolute contraindication to MRI imaging are not eligible for the study
Where in United States
- The SKCCC at Johns HopkinsBaltimore, United States
- Sibley Memorial HospitalWashington D.C., United States
About the trial
What the trial wants to find out
This is a trial that evaluates the preservation of cognition and neuropsychiatric function following genu-sparing whole brain radiation in patients with brain metastases.
The group in the trial
- Corpus Callosum Genu-Sparing Whole Brain Radiation TherapyTreatment being tested
Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
Treatment: whole brain radiation therapy
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Preservation of Cognition and Neuropsychiatric Functioning With Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases: A Pilot Study
- Record updated
- 30 June 2026